lifestyle.ukuncut.org.uk

Author: NEUROCRINE BIOSCIENCES, INC.

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia

April 22, 2026
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results

April 14, 2026
Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR

April 14, 2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

April 6, 2026
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

March 26, 2026
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

March 17, 2026
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum

March 10, 2026
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

February 24, 2026
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026

February 17, 2026
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia

January 26, 2026